about
Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparatorA pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis.Using existing data to identify candidate items for a health state classification system in multiple sclerosis.A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.Acupuncture and multiple sclerosis: a review of the evidence.Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialHow people with multiple sclerosis rate their quality of life: an EQ-5D survey via the UK MS register.Different clinical electrodes achieve similar electrical nerve conduction blockLower urinary tract symptom prevalence and management among patients with multiple sclerosisA comparative study of pelvic floor muscle training in women with multiple sclerosis: its impact on lower urinary tract symptoms and quality of life.Validation of the danish version of functional assessment of multiple sclerosis: a quality of life instrument.Tablet-based screening improves continence management in multiple sclerosisSpasticity in multiple sclerosis and role of glatiramer acetate treatment.Tai chi for health benefits in patients with multiple sclerosis: A systematic review.The impact of slower walking speed on activities of daily living in patients with multiple sclerosis.Perception of Pain Self-efficacy and Fatigue in Greek Patients with Multiple Sclerosis: A Study Protocol.Cross-Sectional Examination of the Associations Between Symptoms, Community Integration, and Mental Health in Multiple Sclerosis.Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait TrainingUK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.Urinary catheterization may not adversely impact quality of life in multiple sclerosis patientsThe TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.Quality of life in multiple sclerosis: effects of current treatment options.Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.Multiple sclerosis spasticity epidemiology--key publications.Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (Management of neurogenic bladder in patients with multiple sclerosis.Country breakout session highlights.Natalizumab treatment of multiple sclerosis: new insights.The impact of walking speed on the effects of functional electrical stimulation for foot drop in people with multiple sclerosis.Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients.Barriers experienced by patients with multiple sclerosis in seeking care for lower urinary tract symptoms.The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis.A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis.
P2860
Q28749656-DCD7CC23-0C93-44DC-9E9E-ACB6BE3C5491Q30547644-295DC0DA-CC93-43D5-A649-4E19F5E639CAQ30715052-EA11EE63-034C-4060-86ED-6E1B3ACE4EA5Q33646171-0A39D747-C2D3-411C-8991-F3F6F8486417Q33863660-24AD0237-BB30-45F7-B0FE-20EB59E25DA2Q34622205-D34D443D-32D3-41C3-8224-02ECB809A9ADQ34775838-AEF2CF72-4721-4616-8775-73FA8B3047DAQ35012943-F2B7FB3E-3C57-4532-A815-E31467CC8616Q35114665-055B1D24-09B1-4E1B-B24B-AD13CB0A0AEDQ35188376-2035E6A2-B248-490A-801E-F791C37C21AEQ35636325-5105C201-8829-4161-B8A3-BBA36CD113F8Q35777277-C0574F44-2F86-4EE6-9F02-0E0D03DA0674Q36109866-26552FC1-C939-4E66-BE55-2221F24A4A9CQ36275161-04376F1D-5A75-4060-BEFD-27D971012A20Q36424217-3A7B2E4D-83D5-4054-B941-01890CBF8DA3Q36622545-5B167118-D7C7-4260-95EA-02D1C8852DC3Q36626879-60465CAB-B558-410E-A758-AD04003CBEC6Q36951356-DD654BB4-1AB8-424B-8554-ED3002F8C99EQ37517082-78F99E5A-C22A-4753-9541-F352411F964FQ37631466-91BA2A66-086C-48F7-96D2-AF82063B9966Q37668551-0F4BCB2C-649F-4C6A-A908-F4557CDFE877Q37710122-7B4D6AC5-F992-4872-92E1-9C55C62C1167Q37859401-E610B8FA-4C0E-4D3C-B2AF-690F62A5F05FQ37884071-95CE0DC7-D2C5-4DFF-AD0F-EB19390A4AEFQ38078055-F6B97A73-569B-4CC8-A98C-97ECE251658DQ38097527-BDD2D9A1-06EB-48F4-A6B2-411E6FE5C46BQ38167395-6F588261-EA93-45F4-A159-F089C75D4DE2Q38167397-E10594B7-4947-41FC-8B6B-45E39B6D849EQ38181065-587DD883-058C-4EB9-8ADB-61D6255FD07DQ38256059-5CD953D0-FF49-4575-8D0B-8EAF5980A359Q38724190-DD4C9FF6-42AB-4B3D-BEC2-120F30FCCEA5Q38794193-8AFA90CA-7493-4185-8297-82E1EBBB35DDQ39016596-65E634A2-3859-4D12-9F73-50EC9EABDE04Q39048568-AD513E4A-7153-4A97-84AB-A4D1DFA9BC3BQ41136282-293847B8-2392-4925-9A48-5DFAE8A4A422Q44483210-1D729F24-2FE8-4172-89D3-4AF552059B61Q45057579-0A6DBEB3-9CE5-47AF-AC9F-7DF8D2852BFAQ46190605-1534DDB6-5DA4-438F-886A-340ED72588CEQ46245009-1D1F0F2B-9CF9-407F-8664-148871F94BC5Q46365444-C05E2005-9429-4A6E-AA3C-A2CE487B4F9F
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
What drives quality of life in multiple sclerosis?
@en
What drives quality of life in multiple sclerosis?
@nl
type
label
What drives quality of life in multiple sclerosis?
@en
What drives quality of life in multiple sclerosis?
@nl
prefLabel
What drives quality of life in multiple sclerosis?
@en
What drives quality of life in multiple sclerosis?
@nl
P2093
P2860
P356
P1476
What drives quality of life in multiple sclerosis?
@en
P2093
P2860
P304
P356
10.1093/QJMED/HCH105
P407
P577
2004-10-01T00:00:00Z